FLNA
Income statement / Annual
Last year (2025), Filana Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Filana Therapeutics Inc's net income was -$90.97 M.
See Filana Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$936.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$22.00 K
|
$58.00 K
|
$69.00 K
|
$68.00 K
|
$58.00 K
|
| Gross Profit |
-$936.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$22.00 K
|
-$58.00 K
|
-$69.00 K
|
-$68.00 K
|
-$58.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$26.59 M
|
$69.64 M
|
$89.42 M
|
$68.03 M
|
$24.81 M
|
$7.29 M
|
$6.30 M
|
$2.97 M
|
$7.62 M
|
$9.18 M
|
| General & Administrative Expenses |
$0.00
|
$71.81 M
|
$16.53 M
|
$11.99 M
|
$8.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$67.86 M
|
$71.81 M
|
$16.53 M
|
$11.99 M
|
$8.06 M
|
$3.72 M
|
$3.33 M
|
$3.62 M
|
$4.27 M
|
$5.72 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$94.45 M
|
$141.45 M
|
$105.96 M
|
$80.02 M
|
$32.87 M
|
$11.01 M
|
$9.63 M
|
$6.59 M
|
$11.88 M
|
$14.90 M
|
| Cost And Expenses |
$95.39 M
|
$141.45 M
|
$105.96 M
|
$80.02 M
|
$32.87 M
|
$11.03 M
|
$9.69 M
|
$6.66 M
|
$11.95 M
|
$14.96 M
|
| Interest Income |
$4.62 M
|
$8.51 M
|
$7.83 M
|
$2.78 M
|
$49.00 K
|
$112.00 K
|
$328.00 K
|
$105.00 K
|
$38.00 K
|
$107.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$936.00 K
|
$1.13 M
|
$1.53 M
|
$1.30 M
|
$534.00 K
|
$22.00 K
|
$58.00 K
|
$69.00 K
|
$68.00 K
|
$58.00 K
|
| EBITDA |
-$90.04 M |
-$141.15 M |
-$105.80 M |
-$80.18 M |
-$31.85 M |
-$11.01 M |
-$9.63 M |
-$6.59 M |
-$11.88 M |
-$14.90 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.42 M
|
$117.10 M
|
$8.74 M
|
$3.77 M
|
$483.00 K
|
$4.70 M
|
$5.06 M
|
$105.00 K
|
$38.00 K
|
$107.00 K
|
| Income Before Tax |
-$90.97 M
|
-$24.34 M
|
-$97.22 M
|
-$76.25 M
|
-$32.39 M
|
-$6.33 M
|
-$4.63 M
|
-$6.56 M
|
-$11.91 M
|
-$14.85 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$90.97 M
|
-$24.34 M
|
-$97.22 M
|
-$76.25 M
|
-$32.39 M
|
-$6.33 M
|
-$4.63 M
|
-$6.56 M
|
-$11.91 M
|
-$14.85 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.88 |
-0.53 |
-2.32 |
-1.9 |
-0.82 |
-0.24 |
-0.27 |
-0.61 |
-1.82 |
-2.31 |
| EPS Diluted |
-1.88 |
-1.46 |
-2.32 |
-1.9 |
-0.82 |
-0.24 |
-0.27 |
-0.61 |
-1.82 |
-2.31 |
| Weighted Average Shares Out |
$48.30 M
|
$46.33 M
|
$41.93 M
|
$40.20 M
|
$39.41 M
|
$26.11 M
|
$17.41 M
|
$10.68 M
|
$6.54 M
|
$6.52 M
|
| Weighted Average Shares Out Diluted |
$48.30 M
|
$4.66 B
|
$41.93 M
|
$40.20 M
|
$39.41 M
|
$26.11 M
|
$17.41 M
|
$10.68 M
|
$6.54 M
|
$6.52 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
